Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: The emerging role for radioembolization using yttrium-90

Oncology (Switzerland)

Volumn 84, Issue 5, 2013, Pages 311-318

  Lau, Wan Yee ^a   Sangro, Bruno ^b   Chen, Pier Jer ^c   Cheng, Shu Qun ^d   Chow, Pierce ^e,f   Lee, Rheun Chuan ^g   Leung, Thomas ^h   Han, Kwang Hyub ⁱ   Poon, Ronnie T P ^j  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

^e SINGAPORE GENERAL HOSPITAL   (Singapore)

^f DUKE NUS MEDICAL SCHOOL   (Singapore)

^g TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^h HONG KONG SANATORIUM AND HOSPITAL   (Hong Kong)

ⁱ Yonsei University   (South Korea)

^j UNIVERSITY OF HONG KONG   (Hong Kong)

more..

Author keywords

Hepatocellular carcinoma; Portal vein tumor thrombosis; Transarterial chemoembolization; Transarterial radioembolization; Yttrium 90

Indexed keywords

MICROSPHERE; SORAFENIB; YTTRIUM 90;

ARTIFICIAL EMBOLISM; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; COLLATERAL CIRCULATION; CONSENSUS; DEATH; EXTERNAL BEAM RADIOTHERAPY; GANGRENE; HUMAN; KOREA; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER TRANSPLANTATION; PARTIAL HEPATECTOMY; PATIENT SELECTION; PORTAL VEIN OBSTRUCTION; PORTAL VEIN TUMOR THROMBOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOEMBOLIZATION; REVIEW; SYSTEMIC THERAPY; TREATMENT CONTRAINDICATION; TUMOR THROMBUS;

EID: 84984578006     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000348325     Document Type: Review

References (51)

1. Yang JD, Roberts LR: Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 2010; 7: 448-458.
2. Bruix J, Sherman M: AASLD practice guideline: management of hepatocellular carcinoma: an update (July 2010). http://www.aasld. org/practiceguidelines/Pages/NewUpdatedGuidelines. aspx (accessed 2012).
3. Ferenci P, Fried M, Labrecque D, et al: World Gastroenterology Organization Guideline. Hepatocellular carcinoma (HCC): a global perspective. J Gastrointestin Liver Dis 2010; 19: 311-317.
4. Pirisi M, Avellini C, Fabris C, et al: Portal vein thrombosis in hepatocellular carcinoma: age and sex distribution in an autopsy study. J Cancer Res Clin Oncol 1998; 12: 397-400.
5. Cheung TK, Lai CL, Wong BCY, Fung J, Yuen MF: Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong. Aliment Pharmacol Ther 2006; 24: 573-583.
6. Minagawa M, Makuuchi M: Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol 2006; 12: 7561-7567.
7. Llovet JM, Bustamante J, Castells A, et al: Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999; 29: 62-67.
8. Schöniger-Hekele M, Müller C, Kutilek M, Oesterreicher C, Ferenci P, Gangl A: Hepatocellular carcinoma in Central Europe: prognostic features and survival. Gut 2001; 48: 103-109.
9. Lau WY, Lai Ee, Yu SC: Management of portal vein tumor thrombus; in Lau WY (ed): Hepatocellular Carcinoma. Singapore, World Scientific Publishing, 2008, pp 739-760.
10. Omata M, Lesmana LA, Tateishi R, et al: Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010; 4: 439-474.
11. Jelic S, Sotiropoulos GC, ESMO Guidelines Working Group: Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(suppl 5):v59-v64.
12. Lau WY, Lai EC: Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int 2008; 7: 237-257.
13. Chen XP, Qiu FZ, Wu ZD, et al: Effects of location and extension of portal vein tumor thrombus on long-term outcomes of surgical treatment for hepatocellular carcinoma. Ann Surg Oncol 2006; 13: 940-946.
14. Shi J, Lai EC, Li N, et al: Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus. Ann Surg Oncol 2010; 17: 2073-2080.
15. Lin DX, Zhang QY, Li X, Ye QW, Lin F, Li LL: An aggressive approach leads to improved survival in hepatocellular carcinoma patients with portal vein tumor thrombus. J Cancer Res Clin Oncol 2011; 137: 139-149.
16. Wu CC, Hsieh SR, Chen JT, et al: An appraisal of liver and portal vein resection for hepatocellular carcinoma with tumor thrombi extending to portal bifurcation. Arch Surg 2000; 135: 1273-1279.
17. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
18. Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomization, double-blind placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
19. Connock M, Round J, Bayliss S, Tubeuf S, Greenheld W, Moore D: Sorafenib for the treatment of advanced hepatocellular carcinoma. Health Technol Assess 2010; 14(suppl 1):17-21.
20. Hawkins MA, Dawson LA: Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer 2006; 106: 1653-1663.
21. Lin CS, Jen YM, Chiu SY, et al: Treatment of portal vein tumor thrombosis of hepatoma patients with either stereotactic radiotherapy or three-dimensional conformal radiotherapy. Jpn J Clin Oncol 2006; 36: 212-217.
22. Shirai S, Sato M, Suwa K, et al: Single photon emission computed tomography-based threedimensional conformal radiotherapy for hepatocellular carcinoma with portal vein tumor thrombus. Int J Radiat Oncol Biol Phys 2009; 73: 824-831.
23. Toya R, Murakami R, Baba Y, et al: Conformal radiation therapy for portal vein tumor thrombosis of hepatocellular carcinoma. Radiother Oncol 2007; 84: 266-271.
24. Zeng ZC, Fan J, Tang ZY, et al: A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus. Int J Radiat Oncol Biol Phys 2005; 61: 432-443.
25. Llovet JM, Real MI, Montanã X, et al: Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739.
26. Lo CM, Ngan H, Tso WK, et al: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171.
27. Llovet JM, Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-442.
28. Luo J, Guo RP, Lai EC, et al: Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol 2011; 18: 413-420.
29. Chung GE, Lee JH, Kim HY, et al: Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology 2011; 258: 627-634.
30. Liapi E, Geschwind JF: Intra-arterial therapies for hepatocellular carcinoma: where do we stand? Ann Surg Oncol 2010; 17: 1234-1246.
31. Kennedy A, Nag S, Salem R, et al: Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the Radioembolization Brachytherapy Oncology Consortium (REBOC). Int J Radiat Oncol Biol Phys 2007; 68: 13-23.
32. Sato K, Lewandowski RJ, Bui JT, et al: Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol 2006; 29: 522-529.
33. Goin JE, Dancey JE, Roberts CA, Sickles CJ, Leung DA, Soulen MC: Comparison of postembolization syndrome in the treatment of patients with unresectable hepatocellular carcinoma: trans-catheter arterial chemoembolization versus yttrium-90 glass microspheres. World J Nucl Med 2004; 3: 49-56.
34. Salem R, Thurston KG: Radioembolization with 90Yttrium microspheres: a state-of-theart brachytherapy treatment for primary and secondary liver malignancies. 1. Technical and methodologic considerations. J Vasc Interv Radiol 2006; 17: 1251-1278.
35. Sangro B, Salem R, Kennedy A, Coldwell D, Wasan H: Radioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendations. Am J Clin Oncol 2011; 34: 422-431.
36. Salem R, Lewandowski RJ, Mulcahy MF, et al: Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138: 52-64.
37. Salem R, Thurston KG: Radioembolization with 90yttrium microspheres: a state-of-theart brachytherapy treatment for primary and secondary liver malignancies. 2. Special topics. J Vasc Interv Radiol 2006; 17: 1425-1439.
38. Riaz A, Lewandowski RJ, Kulik LM, et al: Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol 2009; 20: 1121-1130.
39. Wang SC, Bester L, Burnes JP, et al: Clinical care and technical recommendations for 90yttrium microsphere treatment of liver cancer. J Med Imaging Radiat Oncol 2010; 54: 178-187.
40. Lau W-Y, Kennedy AS, Kim Y-H, et al: Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys 2012; 82: 401-407.
41. Lewandowski RJ, Kulik LM, Riaz A, et al: A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009; 9: 1920-1928.
42. Kooby DA, Egnatashvili V, Srinivasan S, et al: Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2010; 21: 224-230.
43. Carr BI, Kondragunta V, Buch SC, Branch RA. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer 2010; 116: 1305-1314.
44. Salem R, Lewandowski RJ, Kulik L, et al: Radioembolization results in longer time-toprogression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011; 140: 497-507.
45. Hilgard P, Hamami M, Fouly AE, et al: Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010; 52: 1741-1749.
46. Sangro B, Carpanese L, Cianni R, et al: Survival after 90Y resin microsphere radioembolization of hepatocellular carcinoma across BCLC stages: a European evaluation. Hepatology 2011; 54: 868-878.
47. Inãrrairaegui M, Thurston KG, Bilbao JI, et al: Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2010; 21: 1205-1212.
48. Tsai AL, Burke CT, Kennedy AS, et al: Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2010; 21: 1377-1384.
49. Woodall CE, Scoggins CR, Ellis SF, et al: Is selective internal radioembolization safe and effective for patients with inoperable hepatocellular carcinoma and venous thrombosis? J Am Coll Surg 2009; 208: 375-382.
50. Kulik LM, Carr BI, Mulcahy MF, et al: Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008; 47: 71-81.
51. Memon K, Kulik L, Lewandowski RJ, et al: Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression. J Hepatol 2013; 58: 73-80.